MEI Pharma, Inc. (MEIP)

[bladerunner1717]

MEIP presentation at Needham: http://wsw.com/webcast/needham76/meip/index.aspx

Phase III will start before the end of the year. Target enrollment is 500. HR (hazard ratio) to be achieved is .70.

Overall survival (OS) in the Phase II is 16 months and counting. Most analysts had thought that if Pracinostat could achieve a 12-month OS with acceptable side effects, the drug could be approved.

Somebody must have liked the Needham presentation; the volume is exploding.


Bladerunner